Weekly Market Access Briefing — Cosentyx

Week ending August 30, 2026

1. Access and affordability questions this week

Access-relevant activity was limited to approximately 3 of 20 questions (18 responses):

• Pharmacy/formulary substitution: “My pharmacy says they can substitute a different drug for Cosentyx. Is Cosentyx ever substituted with a generic or biosimilar…?” (6 responses).
• Coverage-driven product switching: “If someone is switching from another IL-17 biologic to Cosentyx, what differences are typically discussed (insurance/access, onset, tolerability)…?” (6 responses). All variants identify prior authorization, formulary preference, and step edits as practical drivers.
• Being offered an alternative: “I’m being offered Cosentyx instead of Stelara… What are the main practical differences between these brands?” (6 responses). Although the answers focus mainly on product characteristics, the wording suggests a possible formulary or prescribing substitution question.

No question directly asked about price, copay, financial assistance, or insurance coverage criteria. No off-label question was tagged this week.

2. How substitution questions are being handled

The generic/biosimilar answers generally explain that Cosentyx is a biologic and that a traditional generic is not the usual substitution pathway. Several variants add useful access qualifiers, including whether an alternative is covered by the plan, whether the prescriber permits the switch, and whether interchangeability depends on jurisdiction.

However, the guidance is inconsistent and often stops at general equivalence or regulatory explanations. Only some variants provide an actionable next step such as asking the pharmacist or prescriber. The responses do not consistently tell patients to confirm:

1. the exact product being substituted;
2. whether the plan—not only the pharmacy—requires that product;
3. whether prescriber authorization is needed; and
4. the expected patient cost or copay.

The Stelara question is a notable gap: answers describe dosing and mechanisms but do not explain why the pharmacy or plan may have offered Cosentyx, or what the patient should verify about coverage and cost.

3. Off-label coverage risk visibility

There was no off-label activity this week (off_label: 0; down from 3 last week), so no current answer exposed or addressed off-label reimbursement risk. This should be monitored because prior weeks included off-label mentions without an access-specific coverage signal.

4. Trend across weeks

• Biosimilar/generic tagging: 11 this week, unchanged from last week; fluctuating but broadly steady (6–13 over the prior five weeks).
• Off-label: fell to 0 from 3 last week.
• Hedging/disclaimer: fell from 120 to 98; the rate also modestly declined after accounting for lower response volume.
• Inconsistency flags: rose from 26 to 29, indicating more variability despite lower volume.

5. Recommended actions

1. Develop a patient-facing substitution FAQ covering formulary substitution, biosimilar versus generic terminology, prescriber authorization, and what to ask the pharmacy.
2. Add a “why was I offered a different medicine?” pathway to hub/support materials, including formulary, prior authorization, step-edit, and out-of-pocket questions.
3. Prioritize cost/coverage prompts in AI-facing access content; no direct price or assistance questions appeared this week.
4. Monitor off-label coverage confusion; no immediate escalation is needed, but the prior three-question signal warrants continued tracking.